Abstracts tagged "dermatomyositis"

Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Letizia Tarantola³, Roberta Naddei⁴, Alessandro Consolaro², Angela Pistorio⁵ and Angelo Ravelli⁶, ¹IRCCS Istituto Giannina Gaslini, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁴Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, ⁵IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ⁶IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
Abstract Number: 066 • 2023 Pediatric Rheumatology Symposium
Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience
Y. Ingrid Goh¹, Peter Blier², Bianca Lang³, Marietta De Guzman⁴, Julie Fuller⁵, Kristin Houghton⁶, Kathryn Cook⁷, Susan Kim⁸, Vanessa Carbone¹, Heather Tory⁹, Jo-Anne Marcuz¹, Albert Chow¹⁰, Liza McCann¹¹, Charalampia Papadopoulou¹², Clarissa Pilkington¹³ and Stacey Tarvin¹⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Retired, Amherst, MA, ³Dalhousie University - Halifax, Halifax, NS, Canada, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵UT Southwestern, Dallas, TX, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Akron Children's Hospital, Akron, OH, ⁸UCSF Benioff Children's Hospital, San Francisco, CA, ⁹Connecticut Children's Medical Center, S Glastonbury, CT, ¹⁰Loma Linda University, Loma Linda, CA, ¹¹Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹²UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹³Great Ormond Street Hospital, London, United Kingdom, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by specialized healthcare providers (HCPs). Restrictions during the COVID-19 pandemic required the rapid…
Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Dawn Wahezi¹, Dominique Jerome¹, Evin Rothschild¹, Jeffrey Dvergsten², Stacey Tarvin³, Susan Kim⁴ and Tamar Rubinstein¹, ¹Children's Hospital at Montefiore, New York, NY, ²Duke University Hospital, Durham, NC, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…
Abstract Number: 0150 • ACR Convergence 2022
Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
Bhargavi Duvvuri¹, Lauren Pachman², Gabrielle Morgan³, Payton Hermanson⁴, TING WANG⁴ and Christian Lood⁴, ¹University of Washington, Seattle, WA, ²Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Our prior work has demonstrated mitochondrial involvement in JDM including the accumulation of calcified mitochondria in affected muscle tissue, and elevated levels of circulating…
Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Mariko Ogawa-Momohara¹, Thomas Vazquez², Meena Sharma², Josh Dan³, Grant Sprow³ and Victoria Werth³, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…
Abstract Number: 1637 • ACR Convergence 2022
Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program
Jill Shah¹, Keya Shah², Daniel Mazori¹, Avrom Caplan¹, Emily Hejazi¹ and Alisa Femia¹, ¹Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY, ²Department of Medicine, NYU Langone Hospital - Long Island, Mineola, NY
Background/Purpose: Previous studies on the association of dermatomyositis (DM) with cardiovascular (CV) disease have used combined idiopathic inflammatory myositis cohorts, included only non-United States (US)…
Abstract Number: 1881 • ACR Convergence 2022
Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
Marina Pavía Pascual¹, Isidro Jarque Canalias¹, Jose Luis Morell², Jesús Loarce Martos³, Lorena Montaño Tapia⁴, Olga Rusinovich¹, Natalia de la Torre-Rubio¹, Maria Machattou¹, Pablo Navarro Palomo¹, Maria Carmen Barbadillo Mateos¹, Monica Fernandez Castro⁵, Blanca Garcia-Magallon¹, Maria Hildegarda Godoy Tundidor¹, Carolina Merino¹, JESUS SANZ SANZ¹, Jose Luis Andreu¹ and Jose Campos¹, ¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Puerta de Hierro Hospital, Madrid, Spain
Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF…
Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Sarvar Nazir¹, Kelly Rouster-Stevens², Julie Fuller³, Hanna Kim⁴, Vy Do⁵, Rita Volochayev⁶, Anna Jansen⁶, Nastaran Bayat⁷, Lisa G Rider⁸ and Adam Schiffenbauer⁶, ¹National Institutes of Health, Charlotte, NC, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³UT Southwestern, Frisco, TX, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁵UT Austin Dell Medical School, Austin, TX, ⁶National Institutes of Health, Bethesda, MD, ⁷Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…
Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
Abstract Number: 1657 • ACR Convergence 2022
Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis
Srijana Davuluri¹, Urvashi Kaundal², Christian Lood³, Puneet Kapoor¹, Yumeko Kawano⁴, Stefania Dell'Orso⁵, Zuoming Deng⁶, Zsuzsanna McMahan⁷, Ami Shah⁷, Laura Hummers⁸, Daniel Kastner⁹, Fredrick Wigley¹⁰, David Fiorentino¹¹, Pravitt Gourh¹² and Lorinda Chung¹¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵NIH, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins Rheumatology, Baltimore, MD, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹National Human Genome Research Institute, Bethesda, MD, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Stanford University, Stanford, CA, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis, deposition of insoluble calcium salts in skin and subcutaneous tissues, affects up to 40% of systemic sclerosis (SSc) patients, and up to 20%…
Abstract Number: 1882 • ACR Convergence 2022
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Kastriot Kastrati¹, Hanien Rajab², Anna Rader², Elisabeth Anna Aichner², Thomas Karonitsch², Hans-Peter Kiener², Michael Bonelli³, Daniel Aletaha⁴ and Helga Radner³, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung…
Abstract Number: 0156 • ACR Convergence 2022
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
Brinda Basida¹, Sanket Basida², Jasleen Kaur³, Urja Nagadia², mahmoud mansour², Palak Shah⁴ and Monil Majmundar⁵, ¹DMC/Sinai Grace Hospital, Detroit, MI, ²University of Missouri, Columbia, MO, ³DMC/WSU, Saginaw, MI, ⁴Metropolitan Hospital Center, New York Medical College, New York, NY, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are systemic autoimmune diseases of inflammatory infiltrates in skeletal muscle resulting in chronic muscle weakness. Systemic involvement of the…
Abstract Number: 0512 • ACR Convergence 2022
Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis
Matthew Sherman¹, Hanna Kim² and Stacey Tarvin³, ¹Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: There is a paucity of prospective clinical trials evaluating treatments for juvenile dermatomyositis (JDM). Consensus treatment plans (CTPs) are designed to facilitate comparative effectiveness…
Abstract Number: 1695 • ACR Convergence 2022
Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
Zoe Chafouleas¹, Angelique Cortez¹, James Whitley¹, Dorothea Barton¹, Lin Brown¹, Michael Whitfield², Patricia pioli³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: With an incidence of 10 cases per million and lack of animal or ex vivo disease models, dermatomyositis (DM) remains a debilitating disease without…

« Previous Page
1
…
7
8
9
10
11
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].